Ana W Pacis, NP
Nurse Practitioner · Murrieta
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 3 carriers
- Offices
- 4
- Since medical school
- 6 years
- Graduated 2020
Offices
4 locations · Cep America - California · County of San Mateo
Looking this up.
Hospitals listed: San Mateo Medical Center · Zuckerberg San Francisco General Hosp & Trauma Ctr. That is not proof they admit you there this week.
Plans that list them
4 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Ana W Pacis’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
4 of 4 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| AARP Medicare Advantage from UHC CA-10 (HMO-POS) | UnitedHealthcare | Listed, may be out of date | Jun 10, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- San Mateo Medical CenterSan Mateo, CAAcute Care Hospital · Government - Local · Has an emergency departmentPart of San Mateo County HealthPatients rate it 3 of 5 · 68% would definitely recommend itNo overall ratingNo measure marked better or worse than the national rate
- Zuckerberg San Francisco General Hosp & Trauma CtrSan Francisco, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of San Francisco Health Network, which runs 2 hospitalsPatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.449, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.37, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.538, Oct 2024 – Sep 2025
See every measure and the patient survey for San Mateo Medical Center
Behind the star rating — Deaths: 0 better, 2 the same, 0 worse of 2 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 3 the same, 0 worse of 3 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.34 (0.25 to 2.43) · 45 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.97 (0.48 to 1.47) | No different | Jul 2022 – Jun 2024 |
| Death rate for pneumonia patientsComplications and deaths | 13.9 · 25 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 258 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.44) · 379 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.48) · 381 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.44 (0.82 to 6.05) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.64 (0.92 to 4.37) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.53 (0 to 1.76) · 296 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.661 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.8 · 47 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -2.3 · 25 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 76 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.4 to 18.9) · 167 cases | No different | Jan 2022 – Dec 2024 |
What patients said (208 patients answered, 15% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Zuckerberg San Francisco General Hosp & Trauma Ctr
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 7 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.449 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.37 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.538 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0 to 1.91) · 667 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.12 (0.76 to 1.49) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 195.34 (147.34 to 243.34) · 76 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 114 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.2 · 48 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.5 · 201 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.5 · 214 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 261 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 1,351 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.07 to 0.5) · 4,709 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.39 (0.19 to 0.59) · 4,644 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.34 (2.11 to 6.56) · 795 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.59 (0 to 3.28) · 234 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.85 (1.33 to 4.38) · 861 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.95 (0.25 to 17.64) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6 (2.01 to 9.98) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.17 to 3.14) · 167 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.79 (0.08 to 1.49) · 4,129 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 35 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.709 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.769 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 41 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 227 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 28.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 75.1 · 239 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.2 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.3 (8.3 to 15.1) · 175 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 37 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 132 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.6 (10.4 to 17.9) · 966 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.8 to 1.7) · 88 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,644 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 70% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$3,837
Medicare paid this office $3,837 for 26 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Psychiatric services complicated by communication factor | 12 | $145 | $9 |
Who their Medicare patients are
26 Original Medicare patients in 2024. Average age 64 · Under 65 42% · Women 58% · Health risk score 1.56. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 65% · Depression 65% · Chronic kidney disease 46%.
The office billed $20,863, Medicare allowed $4,974 and paid $3,837; for 53 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 26 | 53 | 64 | 1.56 | $20,863 | $3,837 |
| 2023 | 11 | 21 | 72 | 2.70 | $6,402 | $1,747 |
| 2022 | 26 | 63 | 76 | 1.32 | $18,907 | $4,432 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2022: 1 service
| New patient visit (45+ min) | 11 | $1,270 | $115 |
Medicaid work
$372,410 in 2024
Medicaid paid $372,410 for 4,709 billed services this clinician did in 2024, up to 279 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,483 | $370,841 |
| EMERGENCY DEPT VISIT MOD MDM | 16 | $820 |
| Short return visit (20+ min) | 2,756 | $665 |
| Short return visit | 245 | $51 |
| Annual alcohol misuse screening, 5 to 15 minutes | 48 | $33 |
| Screening for depression is documented as negative, a follow-up plan is not required | 161 | $0 |
| 2024 | 4,709 | 6 | 279 | $372,410 |
Drugs they prescribed that Part D paid
$449,947
Pharmacies billed $449,947 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
3,162 generic and 494 brand-name prescriptions · $449,947 in drug cost · 43 antibiotic prescriptions to 41 people · 23 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 65 | $84,712 | $1,303 |
| Rybelsus | 39 | $55,179 | $1,415 |
| Januvia | 29 | $39,202 | $1,352 |
| Eliquis | 33 | $32,574 | $987 |
| Ozempic | 26 | $28,842 | $1,109 |
See all 60 drugs
| Jardiance | 65 | $84,712 | $1,303 |
| Rybelsus | 39 | $55,179 | $1,415 |
| Januvia | 29 | $39,202 | $1,352 |
| Eliquis | 33 | $32,574 | $987 |
| Ozempic | 26 | $28,842 | $1,109 |
| Vascepa | 25 | $18,994 | $760 |
| Tradjenta | 14 | $16,607 | $1,186 |
| Farxiga | 21 | $14,448 | $688 |
| Icosapent Ethyl | 23 | $11,570 | $503 |
| Tresiba Flextouch U-100 | 11 | $6,057 | $551 |
| Rosuvastatin | 170 | $3,957 | $23 |
| Atorvastatin | 268 | $3,594 | $13 |
| Metformin | 262 | $2,626 | $10 |
| Losartan | 198 | $2,579 | $13 |
| Omeprazole | 151 | $2,272 | $15 |
| Levothyroxine | 137 | $2,155 | $16 |
| Losartan-Hydrochlorothiazide | 85 | $1,861 | $22 |
| Amlodipine Besylate | 248 | $1,719 | $7 |
| Lantus Solostar | 19 | $1,707 | $90 |
| Gabapentin | 87 | $1,519 | $17 |
| Metoprolol | 75 | $1,214 | $16 |
| Mirtazapine | 45 | $1,120 | $25 |
| Lisinopril | 93 | $1,048 | $11 |
| Tamsulosin | 94 | $1,048 | $11 |
| Nano 2nd Gen Pen Needle | 18 | $1,046 | $58 |
| Albuterol Sulfate Hfa | 44 | $787 | $18 |
| Alendronate | 63 | $767 | $12 |
| Simvastatin | 58 | $696 | $12 |
| Trazodone | 36 | $609 | $17 |
| Pioglitazone | 28 | $597 | $21 |
| Hydralazine | 27 | $487 | $18 |
| Metoprolol | 41 | $451 | $11 |
| Duloxetine | 17 | $374 | $22 |
| Diclofenac | 16 | $368 | $23 |
| Famotidine | 25 | $362 | $14 |
| Fluticasone Propionate | 37 | $359 | $10 |
| Allopurinol | 16 | $340 | $21 |
| Finasteride | 15 | $325 | $22 |
| Atenolol | 31 | $324 | $10 |
| Olanzapine | 16 | $302 | $19 |
| Escitalopram | 28 | $282 | $10 |
| Clopidogrel | 24 | $274 | $11 |
| Montelukast | 24 | $270 | $11 |
| Fluoxetine | 11 | $242 | $22 |
| Pravastatin | 16 | $238 | $15 |
| Glipizide | 21 | $229 | $11 |
| Pantoprazole | 18 | $224 | $12 |
| Hydrochlorothiazide | 38 | $215 | $6 |
| Hydroxyzine | 25 | $204 | $8 |
| Memantine | 11 | $185 | $17 |
| Quetiapine | 13 | $180 | $14 |
| Dicyclomine | 11 | $177 | $16 |
| Sertraline | 26 | $161 | $6 |
| Donepezil | 14 | $154 | $11 |
| Carvedilol | 12 | $139 | $12 |
| Risperidone | 15 | $129 | $9 |
| Ibuprofen | 15 | $90 | $6 |
| Meclizine | 12 | $57 | $5 |
| Naproxen | 14 | $50 | $4 |
| Paxlovid | 11 | $0 | $0 |
Year by year
| 2024 | 3,697 | 686 | None | 13% | $449,947 |
| 2023 | 4,245 | 644 | None | 16% | $748,931 |
| 2022 | 490 | 169 | None | 10% | $49,737 |
| 2021 | 554 | 209 | 0% (0) | None | $32,610 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 75 drugs
| Jardiance | 86 | $119,415 | $1,389 |
| Rybelsus | 35 | $85,458 | $2,442 |
| Ozempic | 46 | $51,125 | $1,111 |
| Januvia | 33 | $44,643 | $1,353 |
| Farxiga | 28 | $39,970 | $1,427 |
| Eliquis | 35 | $36,490 | $1,043 |
| Trulicity | 19 | $26,194 | $1,379 |
| Humalog Kwikpen U-100 | 38 | $23,504 | $619 |
| Linzess | 21 | $22,481 | $1,071 |
| Vascepa | 26 | $17,664 | $679 |
| Icosapent Ethyl | 35 | $16,789 | $480 |
| Tradjenta | 12 | $16,117 | $1,343 |
| Lantus Solostar | 30 | $11,642 | $388 |
| Trelegy Ellipta | 16 | $10,760 | $673 |
| Synjardy Xr | 17 | $10,170 | $598 |
| Symbicort | 12 | $7,229 | $602 |
| Rosuvastatin | 180 | $6,565 | $36 |
| Metformin | 253 | $5,641 | $22 |
| Atorvastatin | 217 | $5,537 | $26 |
| Losartan | 211 | $4,808 | $23 |
| Amlodipine Besylate | 248 | $4,501 | $18 |
| Omeprazole | 163 | $3,764 | $23 |
| Levothyroxine | 131 | $3,448 | $26 |
| Metoprolol | 97 | $3,165 | $33 |
| Losartan-Hydrochlorothiazide | 92 | $2,890 | $31 |
| Gabapentin | 117 | $2,720 | $23 |
| Ventolin Hfa | 27 | $2,326 | $86 |
| Tamsulosin | 80 | $2,058 | $26 |
| Lisinopril | 84 | $2,029 | $24 |
| Mirtazapine | 56 | $2,000 | $36 |
| Alendronate | 69 | $1,856 | $27 |
| Simvastatin | 68 | $1,685 | $25 |
| Albuterol Sulfate Hfa | 44 | $1,536 | $35 |
| Fluticasone Propionate | 62 | $1,204 | $19 |
| Betamethasone Dipropionate | 15 | $1,202 | $80 |
| Diclofenac | 37 | $1,113 | $30 |
| Nano 2nd Gen Pen Needle | 16 | $1,097 | $69 |
| Montelukast | 35 | $936 | $27 |
| Famotidine | 32 | $770 | $24 |
| Hydralazine | 35 | $710 | $20 |
| Sertraline | 27 | $705 | $26 |
| Memantine | 12 | $698 | $58 |
| Metoprolol | 48 | $686 | $14 |
| Glimepiride | 18 | $654 | $36 |
| Nitrofurantoin Mono-Macro | 25 | $602 | $24 |
| Hydrochlorothiazide | 46 | $546 | $12 |
| Pioglitazone | 14 | $492 | $35 |
| Naproxen | 45 | $492 | $11 |
| Pregabalin | 18 | $431 | $24 |
| Pantoprazole | 21 | $423 | $20 |
| Hydroxyzine | 20 | $403 | $20 |
| Atenolol | 25 | $388 | $16 |
| Escitalopram | 17 | $369 | $22 |
| Clopidogrel | 19 | $358 | $19 |
| Duloxetine | 18 | $354 | $20 |
| Furosemide | 47 | $344 | $7 |
| Allopurinol | 12 | $324 | $27 |
| Pravastatin | 11 | $324 | $29 |
| Glipizide | 21 | $284 | $14 |
| Promethazine-Dm | 26 | $270 | $10 |
| Ibuprofen | 28 | $265 | $9 |
| Carvedilol | 17 | $264 | $16 |
| Cyanocobalamin | 15 | $216 | $14 |
| Trazodone | 17 | $209 | $12 |
| Dicyclomine | 13 | $194 | $15 |
| Hydrocortisone | 13 | $174 | $13 |
| Triamcinolone Acetonide | 14 | $165 | $12 |
| Meclizine | 23 | $150 | $7 |
| Fluconazole | 15 | $149 | $10 |
| Amoxicillin-Clavulanate Potass | 11 | $132 | $12 |
| Cephalexin | 14 | $128 | $9 |
| Cyclobenzaprine | 11 | $105 | $10 |
| Meloxicam | 11 | $83 | $8 |
| Hydroxyzine Pamoate | 19 | $79 | $4 |
| Prednisone | 15 | $45 | $3 |
2022: 9 drugs
| Losartan-Hydrochlorothiazide | 15 | $934 | $62 |
| Rosuvastatin | 14 | $638 | $46 |
| Albuterol Sulfate Hfa | 11 | $569 | $52 |
| Amlodipine Besylate | 30 | $529 | $18 |
| Omeprazole | 19 | $443 | $23 |
| Atorvastatin | 21 | $417 | $20 |
| Metformin | 30 | $357 | $12 |
| Fluticasone Propionate | 17 | $311 | $18 |
| Promethazine-Dm | 13 | $133 | $10 |
2021: 14 drugs
| Rosuvastatin | 33 | $1,894 | $57 |
| Nitrofurantoin Mono-Macro | 20 | $677 | $34 |
| Omeprazole | 28 | $467 | $17 |
| Clotrimazole-Betamethasone | 12 | $451 | $38 |
| Levothyroxine | 18 | $431 | $24 |
| Amlodipine Besylate | 27 | $420 | $16 |
| Atorvastatin | 23 | $384 | $17 |
| Losartan-Hydrochlorothiazide | 14 | $228 | $16 |
| Metformin | 21 | $201 | $10 |
| Hydroxyzine | 14 | $178 | $13 |
| Losartan | 12 | $172 | $14 |
| Tamsulosin | 13 | $146 | $11 |
| Gabapentin | 12 | $89 | $7 |
| Prednisone | 17 | $30 | $2 |
Money from drug and device companies
$148 in 2025
| 2025 | 2 | 2 | None | $148 |
| 2024 | 3 | 3 | None | $146 |
| 2023 | 17 | 89 | None | $1,670 |
| 2022 | 16 | 85 | None | $1,698 |
| 2021 | 23 | 124 | None | $3,099 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Madrigal Pharmaceuticals | Rezdiffra | $118 | 1 payment
|
| Medtronic | Symplicity G3 | $30 | 1 payment
|
See all 2 published payments
| Medtronic | Meals · 2025-11-20 | Symplicity G3 | $30 |
| Madrigal Pharmaceuticals | Meals · 2025-10-14 | Rezdiffra | $118 |
See earlier years (2024, 2023, 2022, 2021)
2024: $146
| Lilly USA | Mounjaro | $119 | 1 payment
|
| Novo Nordisk | Rybelsus | $14 | 1 payment
|
| Scilex Pharmaceuticals | Elyxyb - Celecoxib | $13 | 1 payment
|
2023: $1,670
| Novo Nordisk | Ozempic | $468 | 32 payments
|
| Abbvie | Vraylar | $268 | 11 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $150 | 9 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $130 | 7 payments
|
| Lilly USA | Mounjaro | $119 | 5 payments
|
| Novartis Pharmaceuticals | Leqvio | $101 | 4 payments
|
| Pfizer | Comirnaty | $82 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $73 | 3 payments
|
| Amgen | Otezla | $52 | 3 payments
|
| Dexcom | Dexcom G6 Transmitter | $50 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $40 | 2 payments
|
| Scilex Pharmaceuticals | Ztlido | $31 | 2 payments
|
| Exact Sciences | Cologuard Collection Kit | $25 | 1 payment
|
| Amarin Pharma | Vascepa | $24 | 1 payment
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $22 | 1 payment
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $20 | 1 payment
|
| Teva Pharmaceuticals USA | Austedo | $15 | 1 payment
|
2022: $1,698
| Novo Nordisk | Rybelsus | $369 | 24 payments
|
| Abbvie | Creon | $257 | 17 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $208 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $189 | 6 payments
|
| Lilly USA | Mounjaro | $120 | 5 payments
|
| Novartis Pharmaceuticals | Leqvio | $91 | 5 payments
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $90 | 4 payments
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $86 | 4 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $64 | 3 payments
|
| Amarin Pharma | Vascepa | $59 | 3 payments
|
| Merck Sharp & Dohme | Belsomra | $43 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $33 | 2 payments
|
| Iti | Caplyta | $31 | 1 payment
|
| Paratek Pharmaceuticals | Nuzyra | $22 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $20 | 1 payment
|
| Teva Pharmaceuticals USA | Austedo | $16 | 1 payment
|
2021: $3,099
| Novo Nordisk | Ozempic | $649 | 32 payments
|
| AbbVie | Vraylar | $507 | 19 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $254 | 6 payments
|
| Biohaven Pharmaceuticals | Nurtec Odt | $245 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $227 | 7 payments
|
| Amarin Pharma | Vascepa | $170 | 12 payments
|
| GlaxoSmithKline | Trelegy Ellipta | $149 | 3 payments
|
| Paratek Pharmaceuticals | Nuzyra | $132 | 3 payments
|
| Merck Sharp & Dohme | Belsomra | $115 | 6 payments
|
| Novartis Pharmaceuticals | Entresto | $105 | 5 payments
|
| Amgen | Evenity | $99 | 4 payments
|
| Sanofi-Aventis U.S. | Toujeo | $85 | 4 payments
|
| Iti | Caplyta | $65 | 3 payments
|
| Becton Dickinson and | Bd Nano | $62 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $44 | 2 payments
|
| Lilly USA | Jardiance | $41 | 2 payments
|
| Teva Pharmaceuticals USA | Austedo | $26 | 1 payment
|
| Mylan Specialty L.P. | Yupelri | $24 | 1 payment
|
| Genentech USA | Xofluza | $23 | 1 payment
|
| Astellas Pharma US | Myrbetriq | $20 | 1 payment
|
| Xeris Pharmaceuticals | Gvoke Pfs | $20 | 1 payment
|
| Pfizer | Eliquis | $20 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $18 | 1 payment
|
Professional record
- NPI
- 1194323121
- Licence
- CA 95015621
- Group
- Cep America - California · County of San Mateo
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 363LP2300X (363LP2300X); Federal specialty code 363LP0808X (363LP0808X)
- Mailing address
- 1886 Eagle Rock Dr, San Marcos, CA, 92069
- NPI first listed
- 2020-10-12
- NPI last updated
- 2024-03-28
- NPI record certified
- 2024-03-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 6991 Balboa Ave, San Diego, CA, 92111